Maria Frantzi, Ana Cristina Morillo, Guillermo Lendinez, Ana Blanca-Pedregosa, Daniel Lopez Ruiz, Jose Parada, Isabel Heidegger, Zoran Culig, Emmanouil Mavrogeorgis, Antonio Lopez Beltran, Marina Mora-Ortiz, Julia Carrasco-Valiente, Harald Mischak, Rafael A Medina, Juan Pablo Campos Hernandez, Enrique Gómez Gómez
{"title":"验证基于尿液的蛋白质组学检验，预测具有临床意义的前列腺癌：与核磁共振成像途径互补","authors":"Maria Frantzi, Ana Cristina Morillo, Guillermo Lendinez, Ana Blanca-Pedregosa, Daniel Lopez Ruiz, Jose Parada, Isabel Heidegger, Zoran Culig, Emmanouil Mavrogeorgis, Antonio Lopez Beltran, Marina Mora-Ortiz, Julia Carrasco-Valiente, Harald Mischak, Rafael A Medina, Juan Pablo Campos Hernandez, Enrique Gómez Gómez","doi":"10.1101/2024.04.16.24305475","DOIUrl":null,"url":null,"abstract":"<strong>Purpose</strong> Prostate cancer (PCa) is the most frequently diagnosed cancer in men. One major clinical need is to accurately predict clinically significant PCa (csPCa). A proteomics based 19-biomarker model (19-BM) was previously developed using Capillary Electrophoresis-Mass Spectrometry (CE-MS) and validated in 1000 patients at risk for PCa. Here, our objective was to validate 19-BM in a multicentre prospective cohort of 101 biopsy-naive patients using current diagnostic pathways.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":"126 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Validation of a urine- based proteomics test to predict clinically significant prostate cancer: complementing MRI pathway\",\"authors\":\"Maria Frantzi, Ana Cristina Morillo, Guillermo Lendinez, Ana Blanca-Pedregosa, Daniel Lopez Ruiz, Jose Parada, Isabel Heidegger, Zoran Culig, Emmanouil Mavrogeorgis, Antonio Lopez Beltran, Marina Mora-Ortiz, Julia Carrasco-Valiente, Harald Mischak, Rafael A Medina, Juan Pablo Campos Hernandez, Enrique Gómez Gómez\",\"doi\":\"10.1101/2024.04.16.24305475\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Purpose</strong> Prostate cancer (PCa) is the most frequently diagnosed cancer in men. One major clinical need is to accurately predict clinically significant PCa (csPCa). A proteomics based 19-biomarker model (19-BM) was previously developed using Capillary Electrophoresis-Mass Spectrometry (CE-MS) and validated in 1000 patients at risk for PCa. Here, our objective was to validate 19-BM in a multicentre prospective cohort of 101 biopsy-naive patients using current diagnostic pathways.\",\"PeriodicalId\":501140,\"journal\":{\"name\":\"medRxiv - Urology\",\"volume\":\"126 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.04.16.24305475\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.04.16.24305475","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Validation of a urine- based proteomics test to predict clinically significant prostate cancer: complementing MRI pathway
Purpose Prostate cancer (PCa) is the most frequently diagnosed cancer in men. One major clinical need is to accurately predict clinically significant PCa (csPCa). A proteomics based 19-biomarker model (19-BM) was previously developed using Capillary Electrophoresis-Mass Spectrometry (CE-MS) and validated in 1000 patients at risk for PCa. Here, our objective was to validate 19-BM in a multicentre prospective cohort of 101 biopsy-naive patients using current diagnostic pathways.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
